Tackling the Opioid Epidemic

Reducing Stigma: The Past, Present and Future of Recovery

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • Other: 0.75
  • Cost: Free
  • Release: Apr 9, 2017
  • Expires: Apr 7, 2023
  • Estimated Time to Complete:
    45 Minutes
  • Average User Rating:
    (20 Ratings)

Faculty

Michelle R.  Lofwall Michelle R. Lofwall, MD, DFASAM
Professor, Psychiatry and Behavioral Science
Center on Drug and Alcohol Research
University of Kentucky College of Medicine
Bell Alcohol and Addictions Chair and Medical Director
First Bridge Clinic
UK HealthCare
Lexington, Kentucky

Needs Statement

Drug overdose is a huge problem facing the health care system in Kentucky. Drug overdose deaths are acute poisoning deaths due to prescription or illicit drugs. According to data from the National Center for Health Statistics, Kentucky had the second highest drug overdose death rate in the U.S. in 2013.

Kentucky Injury Prevention and Research Center - http://www.mc.uky.edu/kiprc/  
Kentucky Department for Public Health http://chfs.ky.gov/dph/  
Released October 2015 

Healthcare professionals encounter patients seeking prescription or illicit drugs in all work settings and routinely provide 24-hour care to patients in hospital. To bring the epidemic to an end, we must ensure access to treatment for addicted patients.

Target Audience

Healthcare professionals prescribing opiates interested in reducing addiction and discovering treatment options for addicted patients.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Define stigma and recovery
  • Identify the core characteristics of a substance use disorder
  • Explain how evidence-based medical treatment and recovery can improve patient, community, and public health
  • Discuss how stigma may interfere with treatment goals

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, Kentucky Office of Drug Control Policy, and Kentucky Injury Prevention and Research Center University of Kentucky College of Public Health (KIPRC). The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0417-H.75-UK9

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Professionalism

Other
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

Michelle Lofwalll, MD (planner and speaker) has relevant financial relationships with commercial interests as follows:

  • Braeburn Pharmaceuticals - Consultant and Principal Investigator - Consulting Fees and Research Contract
  • PCM Scientific - Speaker - Honoraria

No other planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speaker. In some cases, the presentation might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. The speaker will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky, Kentucky Office of Drug Control Policy, and Kentucky Injury Prevention and Research Center University of Kentucky College of Public Health (KIPRC).

Review Date

4/7/2020